The quantitative objective of the current systematic review was to identify the potential role of urinary microbiota in bladder cancer (BC) carcinogenesis, invasiveness, progression, and metastasis.
The proposed systematic review was conducted in accordance with critical review according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement, and the Joanna Briggs Institute (JBI) methodology for systematic reviews. The search strategy aimed to find both published and unpublished studies up to the January 2024. A JBI appraisal checklist was used to assess possible biases.
This systematic review was centered on 27 studies comprising 926 BC patients. Overall, 412 control individuals were compared with BC patients. The most common sampling method was midstream urine collection. Regarding microbial alpha diversity, there was no statistically significant difference between cancerous and healthy samples (n=8), recurrent and not recurrent (n=1), responders versus non-responders(n=1), tumor grades (n=1), and collection methods (n=1). However, five studies reported higher diversity in controls, and five other studies reported, conversely, high levels of alpha diversity in BC patients or recurrent cases. Furthermore, a responder (RE) to treatment and a non-muscle invasive bladder cancer (NMIBC) groups demonstrated significant difference with non-responder (NR) and muscle invasive bladder cancer (MIBC), respectively. In terms of beta-diversity, nine studies reported significant diversity between BC patients and controls, one article demonstrated difference between recurrent and not recurrent patients, a study reported significant difference in RE and NR groups whereas another showed opposite, and others (n=4) did not find any difference between BC, controls, MIBC and NMIBC patients, or between tumor grades. One study reported a difference between the collection method and beta-diversity in males and another reported the difference in females.
The included studies demonstrate that the composition of urinary microbiota is altered in patients with BC. However, the differentially enriched genera in the urine of these patients vary between studies, and there is too much heterogeneity across studies to make any reliable and valid conclusions. Furthermore, well-designed research is necessary to assess the role of microbiota in the carcinogenesis and progression of BC.
Urology journal. 2024 May 07 [Epub ahead of print]
Amir Ghabousian, Ashkan Shafigh, Sona Tayebi, Hanieh Salehi-Pourmehr, Hadi Mostafaei, Ursula Lemberger, Keiichiro Mori, Fatemeh Sadeghi-Ghyassi, Hoora Hassanzadeh, Sakineh Hajebrahimi, Shahrokh F Shariat
Research Center for Evidence-Based Medicine, Iranian EBM Centre: JBI Centre of Excellence, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. ., Research Center for Evidence-Based Medicine, Iranian EBM Centre: JBI Centre of Excellence, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. ., Urology Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. ., Research Center for Evidence-Based Medicine, Iranian EBM Centre: JBI Centre of Excellence, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. ., Research Center for Evidence-Based Medicine, Iranian EBM Centre: JBI Centre of Excellence, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. ., Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. ., Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. ., Research Center for Evidence-Based Medicine, Iranian EBM Centre: JBI Centre of Excellence, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. ., Department of Urology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. ., Research Center for Evidence-Based Medicine, Iranian EBM Centre: JBI Centre of Excellence, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. ., Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/38716613